Welcome to our dedicated page for Im Cannabis SEC filings (Ticker: IMCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp. (Nasdaq: IMCC) has filed a Form F-3 shelf registration allowing it to issue up to $50 million in securities, including common shares, warrants or units combining the two. The filing provides the company with flexibility to raise capital "from time to time" through direct sales, agents, underwriters or dealers, as detailed in the forthcoming prospectus supplements.
The company’s non-affiliate market capitalization was approximately $15.9 million on 26 June 2025, based on 4,044,812 outstanding shares at a May 30 closing price of $6.20. The most recent Nasdaq trading price (25 June 2025) was $2.77 per share. IM Cannabis qualifies as both an emerging growth company (EGC) under the JOBS Act and a foreign private issuer, permitting streamlined disclosure obligations.
The registration statement invokes Rule 415, confirming that the securities may be issued on a continuous or delayed basis. The company has not sold securities under General Instruction I.B.5 in the previous 12 months. Risk disclosures, pricing, fees and use-of-proceeds will be provided in each prospectus supplement, and any related free-writing prospectus may update or modify the base document.
Proceeds are expected to support corporate purposes yet to be specified; investors are cautioned to review the "Risk Factors" section (page 4) once available. No securities may be sold until the SEC declares the shelf effective, and offers are limited to jurisdictions where lawful.